

# Nasopharyngeal Cancer - Pipeline Review, H2 2020

<https://marketpublishers.com/r/N6085FA6FE7EN.html>

Date: August 2020

Pages: 854

Price: US\$ 2,000.00 (Single User License)

ID: N6085FA6FE7EN

## Abstracts

Nasopharyngeal Cancer - Pipeline Review, H2 2020

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2020, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 29, 20, 1, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 4, 7 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

## **Reasons to Buy**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Nasopharyngeal Cancer - Overview

Nasopharyngeal Cancer - Therapeutics Development

Nasopharyngeal Cancer - Therapeutics Assessment

Nasopharyngeal Cancer - Companies Involved in Therapeutics Development

Nasopharyngeal Cancer - Drug Profiles

Nasopharyngeal Cancer - Dormant Projects

Nasopharyngeal Cancer - Discontinued Products

Nasopharyngeal Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Nasopharyngeal Cancer, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020  
Nasopharyngeal Cancer - Pipeline by Akeso Inc, H2 2020  
Nasopharyngeal Cancer - Pipeline by Alphamab Oncology, H2 2020  
Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H2 2020  
Nasopharyngeal Cancer - Dormant Projects, H2 2020  
Nasopharyngeal Cancer - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Nasopharyngeal Cancer, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Advenchen Laboratories LLC  
Akeso Inc  
Alphamab Oncology  
Ambrx Inc  
Apollomics Inc  
Argenx SE  
Ascentage Pharma Group International  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
AVEO Pharmaceuticals Inc  
BeiGene Ltd  
Biomics Biotechnologies Co Ltd  
Bristol-Myers Squibb Co  
Chengdu Wonho Biology Engineering Co Ltd  
China Immunotech Co Ltd  
Cullinan Oncology LLC  
CytoMed Therapeutics Pte Ltd  
Eli Lilly and Co  
Eutilex Co Ltd  
Exelixis Inc  
F. Hoffmann-La Roche Ltd

Geneius Biotechnology Inc  
Guangzhou Double Bioproduct Inc  
Guangzhou Hanghua Bio Pharmaceutical Technology Co  
Harbin Gloria Pharmaceuticals Co Ltd  
Huabo Biopharm Co Ltd  
Immunomic Therapeutics Inc  
Incyte Corp  
Innovent Biologics Inc  
Jiangsu Hengrui Medicine Co Ltd  
Kuur Therapeutics Ltd  
Lion TCR Pte Ltd  
Merck & Co Inc  
Merck KGaA  
Molecular Partners AG  
Nanjing Iaso Biotherapeutics Co Ltd  
Neonc Technologies Inc  
Novartis AG  
Noxopharm Ltd  
Ono Pharmaceutical Co Ltd  
Otsuka Holdings Co Ltd  
Oxford Vacmedix UK Ltd  
PNP Therapeutics Inc  
Polaris Pharmaceuticals Inc  
RAPT Therapeutics Inc  
Shanghai GeneChem Co Ltd  
Shanghai Junshi Bioscience Co Ltd  
Shanghai Miracogen Inc  
Sichuan Kelun Pharmaceutical Co Ltd  
Soricimed Biopharma Inc  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Tessa Therapeutics Ltd  
Tevogen Bio Inc  
TOT Biopharm Co Ltd  
Vectorite Biomedical Inc  
Viracta Therapeutics Inc  
Xencor Inc  
Xiangxue Life Sciences  
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd



## I would like to order

Product name: Nasopharyngeal Cancer - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/N6085FA6FE7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6085FA6FE7EN.html>